bioMérieux bulks up with BioFire – but at too high a price?
This article was originally published in Clinica
Executive Summary
French diagnostics company bioMérieux is consolidating its position in the infectious disease testing market with the planned acquisition of BioFire Diagnostics, a privately held US firm specializing in rapid, multiplex diagnostics. However, with bioMérieux paying $450m, as well as taking on BioFire’s net debt, some analysts believe that the Marcy l’Etoile firm's offer may be overly generous.